Porton Advanced and Yeasen Biotechnology Forge Strategic Partnership to Strengthen CGT Supply Chain Diversification and Collaborative Innovation
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced Powers Qihan Biotech’s Second FDA IND Approval for Allogeneic Dual-Targeting CAR-T Product
China-US Dual Filing Success:Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy
Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
